Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 30;14(9):5178-5180.
doi: 10.21037/tcr-2025-1602. Epub 2025 Sep 25.

Beyond survival: the role of quality of life in modern urothelial cancer therapy

Shugo Yajima  1 , Hitoshi Masuda  1
Affiliations
Editorial

Beyond survival: the role of quality of life in modern urothelial cancer therapy

Shugo Yajima et al. Transl Cancer Res. .
No abstract available

Keywords: Tumor microenvironment; enfortumab vedotin (EV); pain relief; urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-1602/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Gupta S, Loriot Y, Van der Heijden MS, et al. Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. Lancet Oncol 2025;26:795-805. 10.1016/S1470-2045(25)00158-5 - DOI - PubMed
    1. Kepp O, Kroemer G. Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates. Oncoimmunology 2025;14:2533488. 10.1080/2162402X.2025.2533488 - DOI - PMC - PubMed
    1. Yajima S, Hirose K, Masuda H. Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. JAMA Netw Open 2025;8:e250250. 10.1001/jamanetworkopen.2025.0250 - DOI - PMC - PubMed
    1. Fu Z, Gao C, Wu T, et al. Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience 2023;26:107778. 10.1016/j.isci.2023.107778 - DOI - PMC - PubMed

LinkOut - more resources